PEPT, the REX Peptide ETF, is an ETF whose main story is the biology trade.
How it has performed
How PEPT has done, next to the ETFs carrying its narrative and the US market.
| Period | PEPT | The biology trade | US market |
|---|---|---|---|
| Since launch, October 2026 | +4.2% | – | – |
Returns are price change plus dividends. Its narrative is the ETFs carrying the biology trade, combined and weighted by size, leaving out leveraged and inverse ones. A dash means it has not traded for the whole period. Past performance, not a forecast or a recommendation.
Key facts
How it moves
PEPT has traded for less than a year, so how it moves against the market is not shown yet.
Risk
Against its peers
Nearest by size
The ETFs ranked just above and below PEPT by assets, among the 82 ETFs whose main narrative is the biology trade, largest first.
| # | ETF | SHARE | ASSETS | 1 YEAR | COST |
|---|---|---|---|---|---|
| 72 | LGHT | under 0.1% | $2.4m | +4.3% | 0.85% |
| 73 | BIS | – | $1.9m | −49.3% | 0.95% |
| 74 | YUNG | under 0.1% | $929,401 | – | 0.35% |
| 75 | GSKH | under 0.1% | $682,763 | +18.9% | 0.19% |
| 76 | XLVX | under 0.1% | $647,180 | – | 0.45% |
| 77 | TEMC | under 0.1% | $541,370 | – | 0.45% |
| 78 | XBIX | under 0.1% | $535,941 | – | 0.45% |
| 79 | HIMC | under 0.1% | $229,654 | – | 0.45% |
| 80 | NVOC | under 0.1% | $213,115 | – | 0.45% |
| 81 | AIHC | – | – | – | – |
| 82 | PEPT | – | – | – | 0.65% |
Share is each ETF’s slice of the money in ETFs carrying this narrative. 1 year is price change plus dividends; cost is the yearly fee.
Cost against its peers
PEPT is the 46th cheapest of 61 ETFs in the biology trade. The dashed line is the middle of the group, a fee of 0.50% a year.
Where it sits in The biology trade
Each dot is one of 56 plain ETFs whose main narrative is the biology trade, placed by its return (up) and how much it swung (right) over the last year.
The narrative it carries
This is its only narrative.
The biology trade →
Health care from drugmakers and insurers to genomics: the science that gets approved, and who pays for it.
This week its attention level is 46.7, in the WARM band, 19th of 22. 91 ETFs carry it.
How it is built
A plain ETF that owns its holdings directly. It counts toward its narrative's share of money.
Common questions
What story is PEPT selling?
PEPT’s main story is the biology trade, which covers health care from drugmakers and insurers to genomics: the science that gets approved, and who pays for it.
What does PEPT cost?
PEPT charges a yearly fee of 0.65%. It is the 46th cheapest of 61 comparable ETFs.
Is PEPT leveraged?
No. PEPT is a plain ETF: it aims to move one for one with what it holds.
When did PEPT launch?
PEPT launched on October 13, 2026 and is issued by REX.
Run an ETF in the biology trade? StoryVector shows issuers where their ETFs stand against the closest rivals, every week.
Request a pilot